

RECEIVED  
MAY 14 2003  
TECH CENTER 1600/2900  
PTO/STP/STP (05-10)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 1 of 2

Complete if Known	
Application Number	09/944,163
Filing Date	August 30, 2001
First Named Inventor	Schall, Thomas J., et. al.
Art Unit	1617
Examiner Name	Jiang, S. Anna
Attorney Docket Number	019934-000310US

U.S. PATENT DOCUMENTS					
Examiner	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code <sup>2</sup> (if known)			
	AA	US-6,420,121 B1	07/16/2002	J. Nelson et al.	
	AB	US-3,379,729	04/23/1968	M. Protiva et al.	
	AC	US-09/944,051		T. Schall et al.	
	AD	US-10/233,326		B. McMaster et al.	
	AE	US-10/233,336		B. McMaster et al.	
	AF	US-10/061,943		T. Schall et al.	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
598	AG	PCT	WO 00/11950	03/09/2000	Oregon Health Science University		<input type="checkbox"/>
	AH	PCT	WO 02/17900 A2	03/07/2002	ChemoCentryx, Inc.		<input type="checkbox"/>
	AI	PCT	WO 02/17969 A2	03/07/2002	ChemoCentryx, Inc.		<input type="checkbox"/>
	AJ	PCT	WO 02/18954 A2	03/07/2002	ChemoCentryx, Inc.		<input type="checkbox"/>
	AK	PCT	WO 98/02151	01/22/1998	Leukosite, Inc.		<input type="checkbox"/>
598	AL	PCT	WO 00/00491	01/06/2000	The Regents of the University of California		<input type="checkbox"/>

Examiner Signature	<u>598</u>	Date Considered	<u>7/23/03</u>
-----------------------	------------	--------------------	----------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

RECEIVED

MAY 14 2003

TECH CENTER  
600/2900Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page

2

of

2

**Compleat if Known**

Application Number	09/944,163
Filing Date	August 30, 2001
First Named Inventor	Schall, Thomas J., et. al.
Art Unit	1617
Examiner Name	Jiang, S. Anna
Attorney Docket Number	019934-000310US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
SAJ	AM	Beisser, P.S., et al., "Viral Chemokine Receptors and Chemokines in Human Cytomegalovirus Trafficking and Interaction with the Immune System," <i>Curr. Top. Microbiol. Immunol.</i> , Vol. 269, (2002), pp. 203-234.	
	AN	Chee, M.S., et al., "Analysis of the Protein-Coding Content of the Sequence of Human Cytomegalovirus Strain AD169," <i>Curr. Top. Microbiol. Immunol.</i> , Vol. 154, (1990), pp. 125-169	
	AO	Francken, Bart J. B., et al., "Human 5-Hydroxytryptamine <sub>5A</sub> Receptors Activate Coexpressed G <sub>i</sub> and G <sub>o</sub> Proteins in <i>Spodoptera frugiperda</i> 9 Cells", <i>Molecular Pharmacology</i> , Vol. 57, No. 5, pp. 1034-1044 (May 2000).	
	AP	Horuk, Richard, "Molecular properties of the chemokine receptor family", <i>Trends Pharm. Sci.</i> , Vol. 15, (1994), pp. 159-165.	
	AQ	Kledal, T. N., et al., "Selective recognition of the membrane-bound CX <sub>3</sub> C chemokine, fractalkine, by the human cytomegalovirus-encoded broad-spectrum receptor US28," <i>FEBS Letters</i> , Vol. 441, (1998), pp. 209-214.	
	AR	Kung, H. F., et al., "Dopamine D-2 Receptor Imaging Radiopharmaceuticals: Synthesis, Radiolabeling, and in Vigro Biding of (R)-(+)- and (S)-(-)-3-Iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamido, <i>J. of Medicinal Chemistry</i> , Vol. 31, No. 5, (1988), pp. 1039-1042.	
	AS	McNall, Steven J. and Mansour, Tag E., "Novel Serotonin Receptors in <i>Fasciola</i> : Characterization by Studies on Adenylate Cyclase Activation and [ <sup>3</sup> H]LSD Binding", <i>Biochemical Pharmacology</i> , Vol. 33, No. 17, pp. 2789-2797 (1984).	
	AT	Michelson, S., "Cytomegalovirus (CMV) and sequestration of chemokines," <i>Eur. Cytokine Netw.</i> , Vo. 10, No. 2, (June 1999), pp. 286-287.	
	AU	Schall, Thomas J., et al., "Chemokines, leukocyte trafficking, and inflammation", <i>Curr. Opin. Immunol.</i> , Vol. 6, (1994), pp. 865-873.	
	AV	Schall, Thomas J., "Biology of the Rantes/SIS Cytokine Family", <i>Cytokine</i> , Vol. 3, No. 3 (May), (1991), pp. 165-183.	
SAJ	AW	Wang, T. S. T., et al., "A simple Method of Preparation for [ <sup>123</sup> I]-(-)-IBZM, <i>Appl. Radiat. Isot.</i> , No. 4, (1998), pp. 369-372.	

Examiner  
Signature

SAJ

Date  
Considered

7/23/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.  
WC 9057419 v2

MAY 22 2003

TECH CENTER 1600/2906

PTO/SB/08-1 (Rev. 10-01)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

## **Complete if Known**

Application Number	09/944,163
Filing Date	August 30, 2001
First Named Inventor	Schall, Thomas J., et. al.
Art Unit	1617
Examiner Name	Jiang, S. Anna
Attorney Docket Number	019934-000310US

Page 1 of 2

## **U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
SA	AA	US09/944,049		T. Schall et al.	

## **FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AB						<input type="checkbox"/>
	AC						<input type="checkbox"/>
	AD						<input type="checkbox"/>
	AE						<input type="checkbox"/>
	AF						<input type="checkbox"/>
	AG						<input type="checkbox"/>

Examiner  
Signature

SA

Date  
Considered

7/23/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.